Primary Peritoneal Clinical Trials

4 recruiting

Primary Peritoneal Trials at a Glance

66 actively recruiting trials for primary peritoneal are listed on ClinicalTrialsFinder across 6 cities in 38 countries. The largest study group is Phase 2 with 36 trials, with the heaviest enrollment activity in Houston, Boston, and Los Angeles. Lead sponsors running primary peritoneal studies include M.D. Anderson Cancer Center, Mayo Clinic, and National Cancer Institute (NCI).

Browse primary peritoneal trials by phase

Treatments under study

About Primary Peritoneal Clinical Trials

Looking for clinical trials for Primary Peritoneal? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Primary Peritoneal trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Primary Peritoneal clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 66 trials

Recruiting
Phase 2

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC770 enrolled164 locationsNCT06824467
Recruiting
Phase 2

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc310 enrolled91 locationsNCT05128825
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Pancreatic Adenocarcinoma+2 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 3

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Primary Peritoneal CancerFallopian Tube CancerEpithelial Ovarian Cancer
Sichuan Baili Pharmaceutical Co., Ltd.384 enrolled1 locationNCT06994195
Recruiting
Phase 3

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Stage III Ovarian CancerStage IV Ovarian CancerStage III Fallopian Tube Cancer+3 more
GOG Foundation220 enrolled59 locationsNCT05659381
Recruiting

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Malignant Solid Neoplasm+7 more
University of Washington2,000 enrolled1 locationNCT06295965
Recruiting
Phase 1

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

Breast CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma+5 more
M.D. Anderson Cancer Center300 enrolled1 locationNCT03604315
Recruiting
Phase 3

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer+1 more
Imunon500 enrolled7 locationsNCT06915025
Recruiting
Phase 1Phase 2

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Imunon30 enrolled4 locationsNCT05739981
Recruiting
Phase 2

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Primary Peritoneal CancerFallopian Tube CancerNeoadjuvant+1 more
AbbVie140 enrolled57 locationsNCT06890338
Recruiting
Not Applicable

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Carcinoma+4 more
Dana-Farber Cancer Institute240 enrolled6 locationsNCT06710548
Recruiting
Phase 2

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Regeneron Pharmaceuticals220 enrolled50 locationsNCT06787612
Recruiting
Phase 1

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Metastatic Endometrial CarcinomaStage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8+8 more
National Cancer Institute (NCI)42 enrolled6 locationsNCT05691504
Recruiting
Phase 1

Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Abramson Cancer Center at Penn Medicine35 enrolled1 locationNCT02637934
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 1

Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian CancerFallopian Tube CancerPrimary Peritoneal
AstraZeneca24 enrolled9 locationsNCT07402915
Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more
National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401
Recruiting
Phase 1Phase 2

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+13 more
Mayo Clinic40 enrolled3 locationsNCT05920798